Although ovarian cancer harbors TP53 mutations in over 95% of cases, the CHK1/2 inhibitor prexasertib demonstrated a modest clinical response in a phase II clinical trial of BRCA wild-type ovarian cancers [76,77,78]. This evidence concerns the gene TP53 and ovarian carcinoma.